INTRODUCTION
The discovery in 1997 of conceptus-derived cell-free DNA (cf-DNA) in maternal plasma opened the door to highly effective noninvasive prenatal screening and diagnosis [1] . By 2009-2010, it was apparent that prenatal testing was on the threshold of a revolution that would remove many of the barriers that had restricted prenatal testing to only those at high risk for a fetus with a serious condition [2, 3] . It was also recognized that the new testing would raise complex practical and ethical challenges such as the adequacy of pretest patient information and consent, the role of the commercial sector in promoting the testing, the expansion to less severe disorders, and the overall impact on attitudes to individuals with disabilities [3] .
In this article, we revisit some of these issues, review recent progress in resolution, and identify new emerging challenges. We mostly limit this discussion to the use of cf-DNA as a noninvasive prenatal test (NIPT) for the screening of chromosome abnormities; NIPT for monogenic disorders has not yet been widely utilized.
Scope of current testing
The initial major application of cf-DNA analysis focused on the detection of fetal trisomies 21 (Down syndrome), 18 and 13. Numerous clinical trials demonstrated efficacy of NIPT as an advanced ]. Substantially fewer clinical trial data were available for fetal sex chromosome aneuploidies (SCA). However, this testing was also quickly introduced. Some laboratories also now provide testing for a set of clinically well-defined microdeletion syndromes [5 && ,6 && ] or for additional autosomal trisomies that are mostly associated with early miscarriage [7] .
Although these tests are based on cf-DNA, there are multiple molecular technologies, algorithms for data interpretation, policies regarding measurement of fetal fraction, and reporting formats [8 & ]. One of the more important distinctions lies in the use of methods that count DNA fragments versus the analysis of single-nucleotide polymorphisms (SNPs). The latter facilitates distinction of fetal versus maternal abnormalities. Not all methodologies should, therefore, be considered equivalent. All methods analyze DNA that is derived from the placenta, not the fetus.
Depending on the method used, a false-positive or false-negative cf-DNA result can be attributed to true fetal mosaicism [9] , confined placental mosaicism [10 && ], presence of a 'vanished twin' with a karyotype that differs from that of the viable cotwin [11] , the presence of a constitutional or acquired maternal chromosome abnormality including a clinically significant small copy number variant (CNV) [12 && ] and a chromosomal imbalance associated with maternal cancer [13 && ], or testrelated issues such as low fetal fraction.
PROVISION OF NONINVASIVE PRENATAL TEST
Initial clinical trials to evaluate NIPT for fetal trisomies 21, 18, and 13 mostly involved women with a high prior risk on the basis of conventional screening NIPT is generally offered from 9 or 10 weeks gestational age. For a small proportion of women, the test will be unsuccessful, notably those with high maternal weight and early gestational age [4 & ]. Optimal timing of the test requires balancing the possible need to repeat the test, potential provision of alternative screening, follow-up invasive testing for those with positive results, and allowing sufficient time for pregnancy interruption should that be the patient's choice [19 & ].
Management of women with noninvasive prenatal test false-positive results
A troubling set of clinical and ethical issues arises over the management of cases with false-positive results. Some false-positive (and false-negative) NIPT results will be attributable to confined placental mosaicism (CPM) [10 && ]. In these cases, there is an issue as to whether chorionic villus sampling (CVS) will be a consistently reliable confirmatory test because the studies are also based on placental, not fetal, tissue [20 & ]. Some cases of CPM may result in intrauterine growth retardation and additional ultrasound evaluation of these pregnancies later in pregnancy is indicated [19 & ]. Using a counting based approach to NIPT for trisomy 21, 18, and 13, 17% of the false-positive results were attributable to maternal CNVs [12 && ]. These CNVs can have clinical significance [21] , raising the question as to whether additional maternal testing should be offered when there is an otherwise unexplained false-positive result. Maternal chromosome abnormalities are a common cause of SCA false-positives [22 & ]. Even more troubling is the incidental finding of a maternal malignancy in which DNA from an aneuploid tumor is misinterpreted as a fetal chromosome abnormality [13 && ]. It has been suggested that pretest counseling should explain that there could be
KEY POINTS
Clinical providers have experienced difficulty in maintaining up-to-date knowledge about the rapidly expanding role of NIPT in screening for cytogenetic abnormalities.
Some of the difficulties in the introduction of the testing can be attributed to this knowledge gap.
Ethical issues associated with NIPT need to be addressed as new applications emerge and numbers of patients are expanded.
The current normative framework provides a solid basis for evaluating expanded testing for clinically significant disorders.
incidental findings that have implications for maternal health and a consent form should be presented to determine whether the woman wishes to receive these findings [23 & ].
The problem with incidental findings is not unique to NIPT. For example, following conventional screening for Down syndrome it is common to identify an entirely different chromosome abnormality [17 & ]. Provision of an ultrasound exam can also identify a diverse set of abnormalities [24 & ]. It is impractical to counsel patients about all potential findings prior to the provision of cytogenetic studies or a sonogram.
Physician and patient education
The test technicalities, performance, and issues with false-positive results discussed above generally have been poorly understood but are of key importance in the delivery of the testing. For example, from the outset, it was clear that although the sensitivity and specificity far exceeded conventional screening for fetal aneuploidy, the testing was not fully diagnostic and confirmatory testing through an invasive technique (amniocentesis or CVS) was essential for a fully diagnostic result [25] . Because most women who receive cf-DNA screening have an unaffected pregnancy, the proportion of positive results that are false-positives is relatively high. In other words, positive predictive value can be substantially less than 100%. However, poor understanding of this issue has led to some physicians believing that the very high sensitivity and specificity were indicative of diagnostic reliability [26 & ]. Inaccurate marketing materials from some commercial companies have been blamed for contributing to the problem. To be fair, some companies have also made considerable efforts to present data, publish, and communicate with clinical providers because it is in their interests that testing is correctly portrayed. Although the problem of professional and patient education was anticipated [3] , the expansion in the scope and the numbers of patients receiving the testing makes it even more important to bridge the gap between the laboratories and the clinical providers.
Sex chromosome abnormalities and microdeletion syndromes
Except where local laws prohibit the practice, it is common to offer screening for SCA in conjunction with aneuploidy screening. The range of phenotypes associated with SCA is highly variable ranging from early in-utero death to a normal male or female. Patients often readily accept SCA testing because it provides an opportunity for early information about the fetal sex. However, women need to understand that because positive results need to be confirmed, they may be faced with choosing a follow-up invasive test for a potentially mild disorder or dealing with considerable uncertainty at least for the remainder of the pregnancy. Moreover, cf-DNA screening methods that rely on counting frequently identify sex chromosome abnormalities present in the mother [22 & ]. Some of these are likely to be benign manifestations of normal aging, but others may be associated with maternal constitutional chromosomal imbalances. The screening can therefore be the first step toward the discovery of potentially anxiety-provoking incidental findings. However, there is increasing recognition that early diagnosis of SCAs can be beneficial from the perspectives of therapeutic management, creating a supportive environment, and education [27, 28] .
NIPT screening for specific microdeletion syndromes with significant morbidity and mortality has recently been demonstrated [5 && ,6 && ]. Most important of these, the 22q11.2 deletion syndrome has a variably expressed phenotype that can include congenital heart disease, other anatomic abnormalities, immunodeficiency, developmental delay, cognitive deficits, and psychiatric illness [29] . Prenatal screening provides an option for pregnancy interruption for cases with severe fetal abnormalities, or alternatively indicates a need for delivery at a tertiary center, and can help prevent a postnatal 'diagnostic odyssey'. Early treatment of hypocalcemia may prevent seizures and thereby potentially reduce long-term mental disability [30] . Prenatal screening does necessarily involve identification of some maternal deletions, some of which may not have been diagnosed prior to NIPT [5 && ,6 && ]. A recommendation by the European Society of Human Genetics and American Society of Human Genetics is not to offer screening for SCA or microdeletions at this time [31 & ]. However, this proscriptive statement is itself ethically troubling because it restricts patient choice, limits very early detection of cases with severe phenotypes, and fails to recognize that there are potential medical, social, and educational benefits to the early recognition of these disorders. These cases would not necessarily come to early attention without the screening. Alternative guidance is offered by the International Society for Prenatal Diagnosis that discusses the issues associated with testing and emphasizes individual patient autonomy in the provision of NIPT [16 && ].
Quality control and quality assurance
In the United States, all NIPT is currently carried out as 'laboratory developed tests' that are not subject to external validation requirements. Most laboratories do hold certification from the College of American Pathologists that has requirements for laboratories engaged in molecular genetics (including sequencing) and general laboratory procedures. However, there are few specific requirements for NIPT. Considerable attention was recently drawn to this issue when two plasma samples drawn from nonpregnant women were sent to five NIPT laboratories [32 && ]. Two labs reported that there was insufficient fetal DNA but the remaining three each provided a normal NIPT result.
Some NIPT providers are developing instrument and kit-based testing [i.e. in-vitro devices (IVDs)] that would have FDA approval. Separately, the FDA has indicated its intent to develop a regulatory framework for genomic tests. How this will affect quality and future development of NIPT is unclear at this time [33] . In Europe, laboratories are pursuing International Standard, ISO, accreditation for NIPT and CE-marking for IVDs.
General ethical considerations
The expansion of prenatal screening to include additional diverse disorders is being debated by some ethicists [2] . Use of NIPT for the detection of fetal sex for purely nonmedical reasons is sometimes cited as an example of why there needs to be restriction, but this application appears to be exceptional [34] . Broader questions relate to disorders that are mild, late onset, predispositions, and traits. Screening for purely informational purposes with complete reproductive autonomy may be incompatible with the goals of publicly funded screening because it may not be sufficiently cost-effective [35 & ,36 & ]. However, a structure in which screening and choice was limited to only those who could afford it would seem to violate social justice principles. The argument is also predicated on the assumption that a separate monetary value can be placed on each component of the expansion to determine if it is worthwhile from the public health perspective. Others have argued that there is a need to include 'the future person' as a stakeholder because they need protection from psychological harm arising from the information generated [37 & ]. This assumes that the associated limitations on reproductive choice and abortion would be politically acceptable. It also begs the question how the inevitable conflicts between reproductive autonomy and future person rights could be resolved. Ethicists have gone so far as to suggest that there is a need for a new 'normative framework'; i.e. a change in the core ethical and legal principles that justify the practice of prenatal screening [24 & ]. However, the current framework is part of a broader set of medical, social and philosophical ideologies. Even if we acknowledge the exceptional nature of prenatal genetic information, there are practical difficulties in changing the normative framework. Genetic information is becoming increasingly available from multiple sources (carrier screening, newborn screening, other genetic testing, and family health history) and any limitation on NIPT would need to be compatible with these other healthcare initiatives.
IMPROVING NONINVASIVE PRENATAL TESTING
We believe there a number of steps that can be taken by NIPT programs that can minimize many of the current practical and ethical challenges. These are summarized as follows:
(1) Clarity of purpose. It should be recognized that current NIPT is a set of screening tests for a welldefined set of fetal chromosome abnormalities. 
CONCLUSION
Improving clinicians' understanding of the various forms of NIPT available, expected test performance, the significance of positive results, and follow-up patient management are of key importance. There are also steps that NIPT laboratories can consider that may improve service delivery. Current prenatal screening remains substantially focused on clinically significant disorders for which there are benefits associated with early diagnosis. All screening tests implicitly require thoughtful assessment of the trade-off between the identification/reassurance versus the burden associated with false-positive or uncertain findings. The issues for NIPT are not materially different to those present in conventional screening. The current normative framework, which recognizes the primacy of the individual in reproductive healthcare decisions, has provided a solid basis to determine whether screening was worthwhile. We believe this framework needs to be preserved.
